Filing Flows

Filing Flows › Bio-Rad Laboratories (BIO) › Next earnings date

Bio-Rad Laboratories (BIO) earnings: beat the estimate

Bio-Rad Laboratories (BIO) reported on Nov 4, 2026 and beat the EPS estimate: $2.65 against $2.23 (+19.1%). Revenue was $656M for Q3 2026, +0.5% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+19.1% vs estimate
Beat rate60%

The last report

Bio-Rad Laboratories reported revenue of $656M for the third quarter 2026 (+0.5% Y/Y), net earnings $459M: Clinical Diagnostics $402M, Life Science $255M. How it makes money → · Every quarter →

Bio-Rad Laboratories: EPS against the estimate, last 5 reportsBio-Rad Laboratories: EPS against the estimate, last 5 reportsEstimateReported$1.93$2.26Oct 25$2.70$2.51Feb 26$1.99$1.89Apr 26$1.75$2.62Aug 26$2.23$2.65Nov 26
Latest (Nov 26): Estimate $2.23, Reported $2.65.
BIO: the stock's move on each reportBIO: the stock's move on each reportAug 4, 2026+3.9%Apr 30, 2026-6.8%Feb 12, 2026-12.6%Oct 29, 2025-7.8%

Bio-Rad Laboratories' latest quarter

Bio-Rad Laboratories, Q3 2026: revenue $656M (+0.5% year over year), operating margin -7.6%, net earnings $459M, operating cash flow $96.4M. The chart follows the revenue to costs, profit and cash.

Questions

Did Bio-Rad Laboratories beat earnings?

Bio-Rad Laboratories (BIO) reported on Nov 4, 2026 and beat the EPS estimate: $2.65 against $2.23 (+19.1%).

When does BIO report earnings?

The next date is not set yet.

Does Bio-Rad Laboratories usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.